Advanced search
Publication Cover
Expert Review of Ophthalmology Volume 18, 2023 - Issue 6
Submit an article Journal homepage
51
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The long-term clinical outcomes of latanoprostene bunod 0.024% in glaucoma treatment at a tertiary glaucoma center

Jae-Chiang Wonga Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0001-5194-0746View further author information
ORCID Icon,
Rebecca F. Neusteina Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USAView further author information
,
Melih Ustaoglua Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USAView further author information
,
Eric Shiueya Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USAView further author information
,
Nikki Mehrana Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USAView further author information
,
Marlene R. Mostera Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA;b Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USAView further author information
,
Reza Razeghinejada Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA;b Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USAView further author information
,
L. Jay Katza Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA;b Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USAView further author information
,
Jonathan Myersa Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA;b Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USAView further author information
&
Daniel Leea Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA;b Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USACorrespondence[email protected]
View further author information
 show all
Pages 421-427 | Received 09 Jul 2023, Accepted 23 Oct 2023, Published online: 16 Nov 2023

References

  • Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277–e284. doi: 10.1111/aos.13568
  • Wolfram C, Stahlberg E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharmacol Ther. 2019;35(4):223–228. doi: 10.1089/jop.2018.0134
  • Okeke CO, Burstein ES, Trubnik V, et al. Retrospective chart review on real-world use of latanoprostene bunod 0.024% in treatment-naïve patients with open-angle glaucoma. Ophthalmol Ther. 2020;9(4):1041–1053. doi: 10.1007/s40123-020-00307-0
  • Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–745. doi: 10.1136/bjophthalmol-2014-305908
  • Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250–259. doi: 10.1016/j.ajo.2016.05.012
  • Krauss AHP, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2α agonist, in preclinical models. Exp Eye Res. 2011;93(3):250–255. doi: 10.1016/j.exer.2011.03.001
  • Wagner JA, Edwards A, Schuman JS. Characterization of uveoscleral outflow in enucleated porcine eyes perfused under constant pressure. Investig Ophthalmol Vis Sci. 2004;45(9):3203. doi: 10.1167/iovs.03-1176
  • Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a New prostaglandin F2α analog, on aqueous humor dynamics in human eyes. Ophthalmol. 1993;100(9):1297–1304. doi: 10.1016/S0161-6420(93)31484-3
  • Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci. 1994;35(5):2515–2520.
  • Radell JE, Sharma HK, Auyeung KL, et al. Two-Year Experience With Latanoprostene Bunod in Clinical Practice. J Glaucoma. 2021;30(9):776–780. doi: 10.1097/IJG.0000000000001904
  • Araie M, Sforzolini BS, Vittitow J, et al. Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Adv Ther. 2015;32(11):1128–1139. doi: 10.1007/s12325-015-0260-y
  • Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene Bunod 0.024% versus timolol maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension. Ophthalmol. 2016;123(5):965–973. doi: 10.1016/j.ophtha.2016.01.019
  • Wang Y, Liao Y, Nie X. Comparative evaluation of Latanoprostene Bunod, timolol maleate, and latanoprost ophthalmic solutions to assess their safety and efficacy in lowering intraocular pressure for the management of open-angle glaucoma. Clinics. 2020;75:75. doi: 10.6061/clinics/2020/e1874
  • Kawase K, Vittitow JL, Weinreb RN, et al. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612–1627. doi: 10.1007/s12325-016-0385-7
  • Mehta AA, Kanu LN, Sood-Mendiratta S, et al. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma. Eur J Ophthalmol. 2022;32(1):322–326. doi: 10.1177/1120672121998913
  • Okeke CO, Burstein ES, Trubnik V, et al. Retrospective chart review on real-world use of latanoprostene bunod 0.024% in treatment-naïve patients with open-angle glaucoma. Ophthalmol Ther. 2020;9(4):1041–1053. doi: 10.1007/S40123-020-00307-0

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.